Skip to main content
Skip to navigation

Sanofi-aventis and Oxford BioMedica enter licensing agreement

By Chemistry World2007-03-29T15:45:00

Oxford BioMedica has licensed its leading cancer drug, TroVax, to Sanofi-aventis